Dal Yoo
Hematology & Oncology · Washington, DCNPI 1063564532
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.0%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Rigel Pharmaceuticals, Inc. at 44.0% of the total. Reporting peaked in 2019 at $5,287 and has fallen 97.5% since, to $134 in 2024.
Across 77 payments — averaging $77.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rigel Pharmaceuticals, Inc.$3K
- AstraZeneca$797
- Johnson & Johnson$377
- Bristol Myers Squibb$313
- Takeda Pharmaceuticals U.S.A., Inc.$281
- Pharmacyclics LLC, An Abbvie Company$165
- plus $1K from 19 others
What the payments were for
- Consulting fees$5559%
- Speaking & faculty fees$2,00034%
- Travel & lodging$2865%
- Food & beverage$3,08652%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rigel Pharmaceuticals, Inc. | 8 | $2,612 |
| AstraZeneca(2 entities) | 9 | $797 |
| Johnson & Johnson(2 entities) | 12 | $377 |
| Bristol Myers Squibb | 4 | $313 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $281 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $165 |
| Bayer | 4 | $156 |
| Novartis | 4 | $138 |
| Dexcom, Inc. | 1 | $134 |
| Novo Nordisk | 1 | $124 |
| AbbVie | 1 | $110 |
| Daiichi Sankyo Inc. | 5 | $105 |
| Gilead | 1 | $97 |
| Exelixis Inc. | 1 | $94 |
| E.r. Squibb & Sons, L.L.C. | 4 | $88 |
| Janssen Scientific Affairs, LLC | 2 | $67 |
| Jazz Pharmaceuticals Inc. | 1 | $50 |
| Boehringer Ingelheim | 2 | $47 |
| Eisai Inc. | 2 | $39 |
| Pfizer | 2 | $34 |
| EMD Serono, Inc. | 1 | $30 |
| Genentech USA, Inc. | 1 | $22 |
| Puma Biotechnology, Inc. | 1 | $21 |
| Incyte Corporation | 1 | $20 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,936 in reported general payments places this provider in the 55th percentile of 69 hematology & oncology providers in District of Columbia.
See all hematology & oncology providers in District of Columbia →
Other hematology & oncology in Washington
- Imadeddine TabbaraWashington$1.2M
- John MarshallWashington$525K
- Catherine BroomeWashington$504K
- Craig KesslerWashington$449K
- Benjamin WeinbergWashington$326K
- Claudine IsaacsWashington$241K
- Chul KimWashington$173K
- Christopher GallagherWashington$109K
- Neil ShahWashington$76K
- Vered StearnsWashington$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.